Goldman Sachs Removes Onyx Pharmaceuticals (ONXX) from Conviction Buy List

Goldman Sachs removed Onyx Pharmaceuticals (NASDAQ: ONXX) from its Conviction Buy List but maintained a Buy rating and raised its price target to $52 from $47.

The firm sees greater upside in Volcano (Nasdaq: VOLC), which was added to the Conviction Buy List. The analyst notes: 1) VOLC has greater upside (28%) and (2) there is lower upside to our price target for ONXX (16%), which we still consider attractive.

Goldman notes the company is closing in on two key catalysts. They believe expectations for Nexavar Phase 3 data for lung cancer (anticipated this quarter) and potential early FDA approval of CFZ for blood cancer (July 27) remain low.

Goldman bumped FY12 EPS from ($2.82) to ($2.77), FY13 down from ($2.26) to ($3.18) and FY14 down from ($1.12) to ($1.92).

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $45.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Alkem Laboratories Ltd (ALKEM:IN) PT Lowered to INR6,850 at Nomura/Instinet
• LG Electronics India (LGEL:IN) PT Raised to INR1,983 at Nomura/Instinet